Nipocalimab is a medicine used to treat generalized myasthenia gravis and warm autoimmune hemolytic anemia. It works by lowering the levels of harmful antibodies that attack the body's own muscles or red blood cells. It's given as an infusion into a vein.
Every report comes from a Lived member, sent anonymously.
Have you tried Imaavy (Nipocalimab) for Myasthenia Gravis?
Nipocalimab, sold as Imaavy, is a prescription infusion medicine for two autoimmune conditions in which the immune system makes antibodies that attack the body's own tissue. It is approved for adults and children 12 and older. The first is generalized myasthenia gravis, a condition that causes muscle weakness that worsens with use, often affecting the eyes, face, swallowing, breathing and limbs. Nipocalimab is approved only for people whose blood tests show one of two specific antibodies: anti-acetylcholine receptor (AChR) antibodies, which target the spot on muscle where nerve signals arrive, or anti-MuSK antibodies, which target a muscle protein that helps keep that spot working. These two antibody types account for most cases. The second is warm autoimmune hemolytic anemia (wAIHA), in which antibodies coat red blood cells so the body destroys them faster than it can replace them, causing anemia. Nipocalimab is approved for people with wAIHA who are taking or have already taken corticosteroids, which are usually the first treatment. In both conditions it is generally added to existing treatment rather than replacing it.
Antibodies of the IgG type, the kind that drive both of these conditions, normally survive in the blood for weeks. They last that long because a protein called the neonatal Fc receptor (FcRn) rescues them from being broken down inside cells and returns them to the bloodstream. Nipocalimab is a laboratory-made antibody that blocks this receptor. Without that rescue, IgG antibodies are broken down faster and their levels in the blood drop, including the harmful autoantibodies that weaken muscle signals or destroy red blood cells. With less of these autoantibodies circulating, symptoms can ease. The effect is temporary and reverses as the drug wears off, which is why infusions are repeated on a schedule. It does not switch off the immune system's production of these antibodies, so it controls the disease rather than curing it.
Nipocalimab is given only as an intravenous infusion, a slow drip into a vein, at an infusion center or clinic. The dose is calculated from body weight. For myasthenia gravis, treatment starts with a larger first infusion, followed two weeks later by a smaller maintenance dose that continues every two weeks. For wAIHA, the same size dose is repeated every four weeks after the first. The first infusion takes at least 30 minutes and later ones at least 15 minutes, and staff watch for reactions during each infusion and for 30 minutes afterward. If a scheduled infusion is missed, it is usually given as soon as possible and the regular interval then continues from that date. Before treatment begins, the care team will check whether any vaccines are due.
In people with myasthenia gravis, the most common side effects in studies were respiratory infections such as colds and bronchitis, swelling in the legs or ankles, and muscle spasms. In people with wAIHA, the most common were swelling, diarrhea and fever. Some people have an infusion reaction such as headache, flu-like feelings, chills, nausea, tiredness, dizziness or flushed skin, usually within a day or two and mostly mild. Allergic reactions such as rash or hives can happen during the infusion or up to two weeks later, and should be reported to the care team right away. Rarely, a reaction can be severe: trouble breathing or swelling of the face, lips, tongue or throat after leaving the clinic needs emergency care, so call 911. Because nipocalimab lowers protective antibodies too, infections are more likely. Tell the care team about fever, chills, a new cough, painful urination or a painful blistering rash, which can signal shingles.
The main trade-off is infection risk. In long-term studies, about 7 in 100 people with myasthenia gravis and 12 in 100 with wAIHA had a serious infection. Infusions are usually postponed during an active infection, and dormant viruses, such as the one that causes shingles, can reactivate. Anyone who has had a serious allergic reaction to nipocalimab should not receive it again. Vaccines are best brought up to date before starting. Live vaccines, which contain a weakened form of the germ, are not recommended during treatment, and how well other vaccines work during treatment is not known. Mention nipocalimab before any vaccination. Nipocalimab can also clear other antibody-based medicines from the body faster, making them less effective. This includes immunoglobulin (IVIG), donated antibodies sometimes used for myasthenia gravis flares, and monoclonal antibody drugs used for many conditions. Make sure every prescriber knows about it. There is little information on use in pregnancy. In animal studies it damaged the placenta and was linked to pregnancy loss. Because it blocks the antibodies a mother passes to her baby, an infant exposed late in pregnancy may have weaker protection against infection for six months or more, and live vaccines for the baby may need to be reconsidered. It also passes into breast milk. Anyone pregnant, planning pregnancy or breastfeeding should discuss this with the care team. It can also raise cholesterol, mostly in the first weeks, so lipid levels may be checked.
Antibody levels fall quickly after the first infusion. In the main myasthenia gravis study, which lasted 24 weeks and added nipocalimab to usual treatment, people on the drug improved more than those on placebo in everyday tasks the disease typically affects and in measured muscle strength. The extra improvement averaged about 1.5 points on a 24-point daily-activities scale, and individual responses varied. In the wAIHA study, about 1 in 4 people on nipocalimab reached a steady, meaningful rise in hemoglobin (the oxygen-carrying protein in red blood cells, measured in a blood test) over 24 weeks, compared with fewer than 1 in 10 on placebo. Fatigue improved modestly. Many people did not reach that target, so the care team will judge response through repeat blood counts. Because the effect wears off between infusions, treatment is ongoing for as long as it helps, with regular infusion visits, checks for infection and periodic reviews of the overall treatment plan. Longer-term experience with this newly approved medicine is still being gathered.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Imaavy (Nipocalimab), what you've noticed, or ask the community a question.